Navigation Links
Regenesis Biomedical Names Scott Brooks Chief Executive Officer
Date:5/14/2013

SCOTTSDALE, Ariz., May 14, 2013 /PRNewswire/ -- Regenesis Biomedical, Inc., a medical technology company focused on tissue regeneration, announced today that the Board of Directors has unanimously elected Scott Brooks as the next Chief Executive Officer (CEO), and member of the Board of Directors, succeeding Virginia Rybski .  Brooks will assume his new role immediately.

(Photo: http://photos.prnewswire.com/prnh/20130514/LA13597)

(Logo: http://photos.prnewswire.com/prnh/20120109/LA31405LOGO)

Brooks, Regenesis' Chief Operating Officer since January 2012, will become the fourth CEO in Regenesis' history.  Virginia Rybski , previous CEO, recently lost her battle with pancreatic cancer. 

"After a thorough and deliberate selection process last year for the newly created COO position, the Board of Directors is delighted that Brooks will lead Regenesis as we finalize plans for clinical trials and expand reimbursement coverage," said John Voris , Chairman of the Board of Directors.  "His knowledge and understanding of the issues important to our growth and value creation will ensure our continued success."  

Scott Brooks ' career spans senior management positions in BSN medical, KCI, Hill-Rom Company and Kimberly-Clark Healthcare, across sales and marketing, business development, national accounts and operations.  He holds a Bachelor of Arts degree in Business Administration with emphasis in marketing from Western Washington University.  He also is a graduate of the Looking Glass Experience conducted by the Center for Creative Leadership.  In addition, he attended the executive management program at the University of Michigan Graduate School of Business.  As a seasoned executive, Mr. Brooks brings not only impressive experience, but also a new and energizing vision for Regenesis.  He possesses broad knowledge of the health care industry including many contacts with key thought-leaders in the industry.  Scott is also a former executive committee member of the Federation of American Hospital Systems and was on the board at the American College of Phlebology Foundation.

"I look forward to leading Regenesis and our fantastic team of dedicated colleagues.  With our innovative device, excellent sales and marketing organization, customer focused support team and close client relationships, we can expand our therapeutic relief to many of the millions of pain suffers in the U.S. and abroad," says CEO elect Scott Brooks .  "As we continue to add to the clinical body of evidence for Provant Therapy, I am convinced we will deliver on our long term growth targets in the coming years.  I am also pleased that the current senior management team will continue in the new leadership structure."

Regenesis has treated over 8,000 patients and attained greater than a 97% patient satisfaction score.  Provant Therapy is an innovative medical device that delivers pulsed electromagnetic therapy at home.  This non-narcotic pain relief is proven to be safe, easy to use and effective.  Since 2003, the company has delivered average annual growth rates of 11-12%.

About Regenesis Biomedical

Regenesis Biomedical, Inc. is a privately held medical technology company focused on developing and marketing noninvasive regenerative medicine products.  Regenesis developed, patented, and now markets the Provant Therapy System.  Our customers include health care facilities, acute care hospitals, long-term acute care hospitals, skilled nursing facilities, rehabilitation centers, home health care agencies, and outpatient clinics.

About the Provant® Therapy System

Provant uses pulsed radio frequency energy (PRFE) to facilitate reduction of the pain and edema associated with post-operative, superficial soft tissues.

Contact: Regenesis Biomedical, Inc.
Scott Robey , Vice President Marketing
www.regenesisbio.com
480-970-4970 phone


'/>"/>
SOURCE Regenesis Biomedical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Scott Brooks Joins Regenesis Biomedical as Chief Operating Officer
2. Premier Biomedical CEO Interviewed by The Wall Street Transcript
3. ICMs New Blue Gene Supercomputer Supports The Largest Biomedical Research Initiative In Poland
4. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
5. Lupus Research Institute Requests Strengthened NIH Funding for Biomedical Research in Debilitating Diseases like Lupus
6. Fourth Annual Bay Area Biomedical Device Conference: March 27th, 2013 at San Jose State University
7. Foundation for the NIH Announces Lurie Prize Recognizing Outstanding Achievement by a Young Biomedical Scientist
8. ABIA Hires Biomedical Executive, Serial Entrepreneur as Chief Operating Officer
9. Market Outlook: The Future of Biomedical Materials
10. California Biomedical Companies Report Higher Product Approvals, Fewer Delays
11. Fujimoto Honored with Britton Chance Biomedical Optics Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity of ... performing systematic gain-of-function studies. , This complement to loss-of-function studies, such as ...
(Date:10/11/2017)... a leading provider of patient support solutions, has announced the ... which will launch this week. The VMS CNEs will address ... enhance the patient care experience by delivering peer-to-peer education programs ... to help women who have been diagnosed and are being ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator ... osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular STAT3 ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and ... San Diego Rotary Club. The event entitled “Stem Cells and Their ... 300+ attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: Peter ...
Breaking Biology Technology:
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. ... company, announces the filing of its 2016 Annual Report on Form ... Exchange Commission. ... Form 10-K is available in the Investor Relations section of the ... on the SEC,s website at http://www.sec.gov . 2016 ...
(Date:4/11/2017)... DUBLIN , Apr. 11, 2017 Research ... Tracking Market 2017-2021" report to their offering. ... The global eye tracking market to grow at ... The report, Global Eye Tracking Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
Breaking Biology News(10 mins):